

AKR7A3 Blocking Peptide (Center)

Synthetic peptide

Catalog # BP21988c

Specification

AKR7A3 Blocking Peptide (Center) - Product InformationPrimary Accession [O95154](#)**AKR7A3 Blocking Peptide (Center) - Additional Information**

Gene ID 22977

Other Names

Aflatoxin B1 aldehyde reductase member 3, 1.-.-., AFB1 aldehyde reductase 2, AFB1-AR 2, AKR7A3, AFAR2

Target/Specificity

The synthetic peptide sequence is selected from aa 207-217 of HUMAN AKR7A3

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

AKR7A3 Blocking Peptide (Center) - Protein Information

Name AKR7A3

Synonyms AFAR2

Function

Can reduce the dialdehyde protein-binding form of aflatoxin B1 (AFB1) to the non-binding AFB1 dialcohol. May be involved in protection of liver against the toxic and carcinogenic effects of AFB1, a potent hepatocarcinogen.

Cellular Location

Cytoplasm.

Tissue Location

Expressed in colon, kidney, liver, pancreas, adenocarcinoma and endometrium.

AKR7A3 Blocking Peptide (Center) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

AKR7A3 Blocking Peptide (Center) - Images

AKR7A3 Blocking Peptide (Center) - Background

Can reduce the dialdehyde protein-binding form of aflatoxin B1 (AFB1) to the non-binding AFB1 dialcohol. May be involved in protection of liver against the toxic and carcinogenic effects of AFB1, a potent hepatocarcinogen.

AKR7A3 Blocking Peptide (Center) - References

Knight L.P., et al. Carcinogenesis 20:1215-1223(1999).
Praml C., et al. Oncogene 22:4765-4773(2003).
Gregory S.G., et al. Nature 441:315-321(2006).
Bodreddigari S., et al. Chem. Res. Toxicol. 21:1134-1142(2008).